These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17575229)

  • 1. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
    Bommakanti SV; Dudek AZ; Khatri A; Kirstein MN; Gada PD
    Am J Clin Oncol; 2011 Dec; 34(6):597-602. PubMed ID: 21127410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Crul M; Schoemaker NE; Pluim D; Maliepaard M; Underberg RW; Schot M; Sparidans RW; Baas P; Beijnen JH; Van Zandwijk N; Schellens JH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3526-33. PubMed ID: 14506138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
    Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
    J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
    Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
    J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
    Reck M; Frickhofen N; Cedres S; Gatzemeier U; Heigener D; Fuhr HG; Thall A; Lanzalone S; Stephenson P; Ruiz-Garcia A; Chao R; Felip E
    Lung Cancer; 2010 Nov; 70(2):180-7. PubMed ID: 20188433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
    Luu T; Chow W; Lim D; Koczywas M; Frankel P; Cristea M; Margolin K; Doroshow JH; Somlo G; Gaur S; Yen Y; Morgan RJ
    Anticancer Res; 2010 Jan; 30(1):167-74. PubMed ID: 20150632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma.
    Froudarakis ME; Pataka A; Pappas P; Anevlavis S; Argiana E; Nikolaidou M; Kouliatis G; Pozova S; Marselos M; Bouros D
    Cancer; 2008 Nov; 113(10):2752-60. PubMed ID: 18823054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.
    Parra HS; Cavina R; Latteri F; Campagnoli E; Morenghi E; Torri W; Brambilla G; Alloisio M; Santoro A
    Invest New Drugs; 2007 Feb; 25(1):57-62. PubMed ID: 16699975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
    Guarino MJ; Schneider CJ; Grubbs SS; Biggs DD; Himelstein AL; Hogaboom K; Tilak S
    Oncologist; 2002; 7(6):509-15. PubMed ID: 12490738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.